News and updates

Viewing:

All Years 2024 2023 2022 & Older

July 12, 2021

AMRI becomes Curia

Albany Molecular Research, Inc. (AMRI), a leading global contract research, development and manufacturing organization serving the pharmaceutical and biopharmaceutical industries, today announced that it is changing its name to Curia, effective July...

April 30, 2021

Curia Adds to Accelerated R&D and Manufacturing Solutions for Orphan Products to Treat Rare Diseases

Albany Molecular Research, Inc. (AMRI), a leading global provider of advanced contract research, development and manufacturing solutions, today announced expanded access to its accelerated solutions platform, spanning research & development to manuf...

March 9, 2021

Curia Earns Spot on Forbes America’s Best Employers 2021 List

Albany Molecular Research, Inc. (AMRI), a leading global provider of advanced contract research, development and manufacturing solutions, today announced that the company is named on “America’s Best Mid-Sized Employers 2021” list published by...

February 25, 2021

Curia Joins Network of Approved Manufacturers of Lipid Excipients for Pfizer-BioNTech COVID-19 Vaccine

Albany Molecular Research, Inc. (AMRI), a leading global provider of advanced contract research, development and manufacturing solutions, today announced that the company has been chosen to support the development and manufacture of lipid excipients...

February 8, 2021

AMRI Appoints Scott Waldman to Lead Corporate Development

Albany Molecular Research, Inc. (AMRI), a leading global provider of advanced contract research, development and manufacturing solutions, today announced the appointment of Scott Waldman as senior vice president, Corporate Development for AMRI. Waldm...

February 1, 2021

AMRI Wins 2021 CMO Leadership Awards — Recognized in All Six Performance Categories

Albany Molecular Research, Inc. (AMRI), a leading global provider of advanced contract research, development and manufacturing solutions, today announced it has been recognized in the 2021 CMO Leadership Awards, presented by Outsourced Pharma and Lif...

January 11, 2021

AMRI Included in BARDA CDMO Network in Support of COVID-19 Pandemic Response in the U.S.

Albany Molecular Research, Inc. (AMRI), a leading global provider of advanced contract research, development and manufacturing solutions, today announced its Albuquerque, New Mexico, facility has been approved for inclusion in the Biomedical Advanced...

November 4, 2020

AMRI Named Exclusive API Supplier for Recently Approved Acne Treatment

Albany Molecular Research, Inc. (AMRI) today announced that it has been named as the exclusive supplier of the active pharmaceutical ingredient (API) in Cassiopea SpA’s (SIX: SKIN) recently approved acne treatment, Winlevi® (clascoterone) cream 1...

September 3, 2020

AMRI Selected to Support AstraZeneca in Delivery of COVID-19 Vaccine

Albany Molecular Research, Inc. (AMRI), a leading global provider of advanced drug development and manufacturing solutions, today announced that it has signed a supply agreement with AstraZeneca to support the manufacture of AstraZeneca’s COVID-19...

August 3, 2020

Tryp Therapeutics Partners With Albany Molecular Research Inc. To Manufacture a Proprietary Psilobycin-Based Drug

Tryp Therapeutics Inc. (“Tryp” or the “Company”), a clinical-stage pharmaceutical company developing therapeutics targeting diseases with high unmet medical needs, announced today it has entered into an agreement with Albany Molecular Researc...

July 8, 2020

ViralClear Pharmaceuticals Partners with AMRI on the Manufacture of Merimepodib API in Development for the Potential Treatment of COVID-19

ViralClear Pharmaceuticals, Inc. (ViralClear), supported by Albany Molecular Research Inc., (AMRI), a leading global contract research, development, and manufacturing organization (CDMO), is undertaking research to investigate the potential of meri...

June 11, 2020

BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1 Synthesized by AMRI

BryoLogyx Inc. today announced it has entered into two agreements with Neurotrope, Inc. (Nasdaq: NTRP) to acquire Neurotrope’s preclinical data package and drug product for use of bryostatin-1 in an immuno-oncology application, and to supply Neurot...

1 2 3 4

Ready to move from idea to impact?

Whether you have a question for our team or an opportunity you’re eager to pursue, one of our experts can help you get started.

Get started